中川崇

ナカガワタカシ | NAKAGAWA TAKASHI

所属機関・部署：
職名：教授
ホームページURL (1件)： http://www.med.u-toyama.ac.jp/pharma/

研究分野 (4件)：代謝、内分泌学 , 栄養学、健康科学 , 薬理学 , 医化学

研究キーワード (4件)： NAD代謝 , メタボロミクス , 老化 , ミトコンドリア

論文 (61件)：

Katsuhiko Kamei, Yasuhito Yahara, Jun-Dal Kim, Mamiko Tsuji, Mami Iwasaki, Hiroshi Takemori, Shoji Seki, Hiroto Makino, Hayato Futakawa, Tatsuro Hirokawa, et al. Impact of the SIK3 pathway inhibition on osteoclast differentiation via oxidative phosphorylation. Journal of Bone and Mineral Research. 2024. 39. 9. 1340-1355
Mathieu Membrez, Eugenia Migliavacca, Stefan Christen, Keisuke Yaku, Jennifer Trieu, Alaina K. Lee, Francesco Morandini, Maria Pilar Giner, Jade Stiner, Mikhail V. Makarov, et al. Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia. Nature Metabolism. 2024. 6. 433-447
Tooba Iqbal, Takashi Nakagawa. The therapeutic perspective of NAD+ precursors in age-related diseases. Biochemical and Biophysical Research Communications. 2024. 702. 149590
Allah Nawaz, Azhar Manzoor, Saeed Ahmed, Naveed Ahmed, Waseem Abbas, Mushtaq Ahmad Mir, Muhammad Bilal, Alisha Sheikh, Saleem Ahmad, Ishtiaq Jeelani, et al. Therapeutic approaches for chronic hepatitis C: a concise review. Frontiers in Pharmacology. 2024. 14
Miyuki Nomura, Mai Ohuchi, Yoshimi Sakamoto, Kei Kudo, Keisuke Yaku, Tomoyoshi Soga, Yuki Sugiura, Mami Morita, Kayoko Hayashi, Shuko Miyahara, et al. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma. Nature Communications. 2023. 14. 1. 8095

学歴 (2件)：

経歴 (3件)：

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

中川 崇